RC 68
Alternative Names: RC-68Latest Information Update: 28 Feb 2023
At a glance
- Originator Yantai Rongchang Pharmaceutical
- Developer RemeGen; Yantai Rongchang Pharmaceutical
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors; Immunomodulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in China (Parenteral)
- 11 Jan 2019 Pharmacodynamics data from a preclinical trial in pancreatic cancer released by RemeGen
- 01 Jan 2019 Preclinical trials in Pancreatic cancer in China (Parenteral) before January 2019 (Yantai Rongchang Pharmaceuticals pipeline, January 2019)